Tanshinone IIA Exerts an Antinociceptive Effect in Rats with Cancer-induced Bone Pain
Cancer-induced bone pain (CIBP) is a common chronic pain characterized by 2 components, ongoing pain and breakthrough pain. Tanshinone IIA (TSN IIA) is a bioactive constituent of the traditional Chinese medicine Danshen, which has been reported to have an antinociceptive effect on neuropathic and in...
Gespeichert in:
| Veröffentlicht in: | Pain physician 2016-09, Vol.19 (7), p.465-476 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 476 |
|---|---|
| container_issue | 7 |
| container_start_page | 465 |
| container_title | Pain physician |
| container_volume | 19 |
| creator | Hao, Wei Chen, Lei Wu, Li-Fang Yang, Fan Niu, Jian-Xiang Kaye, Alan D Xu, Shi-Yuan |
| description | Cancer-induced bone pain (CIBP) is a common chronic pain characterized by 2 components, ongoing pain and breakthrough pain. Tanshinone IIA (TSN IIA) is a bioactive constituent of the traditional Chinese medicine Danshen, which has been reported to have an antinociceptive effect on neuropathic and inflammatory pain through downregulation of the late proinflammatory cytokine high-mobility group protein B1 (HMGB1).
To assess the antinociceptive effect of TSN IIA on CIBP.
A randomized, double-blind, controlled animal trial was performed.
University lab in China.
A rat CIBP model was established by injecting Walker 256 mammary gland carcinoma cells into the intramedullary cavity of the tibia. Both ongoing pain, e.g., flinching and guarding, and breakthrough pain, e.g., limb use and von Frey threshold, were evaluated. The effects of intraperitoneally administered TSN IIA on pain behavior and the expression levels of spinal HMGB1, interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6 were determined. The effect of TSN IIA on the electrically evoked response of spinal wide-dynamic range (WDR) neurons was performed in vivo.
TSN IIA dose-dependently inhibited cancer-induced ongoing pain and breakthrough pain. The expression levels of spinal HMGB1 and other inflammatory factors (IL-1beta, TNF-alpha, and IL-6) were increased in the rat model, but they were suppressed by TSN IIA in a dose-dependent manner. Moreover, TSN IIA significantly inhibited the neuronal responses of WDR neurons in spinal deep layers.
Further studies are warranted to ascertain how TSN IIA attenuates cancer-induced ongoing pain.
Our results indicate that TSN IIA attenuates cancer-induced ongoing pain and breakthrough pain, possibly via suppression of central sensitization in CIBP rats. Therefore, we have provided strong evidence supporting TSN IIA as a potential and effective therapy for relieving CIBP.
Cancer-induced bone pain, high-mobility group protein B1, Tanshinone IIA, ongoing pain, breakthrough pain. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1824545821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1824545821</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-d6e21aca479fd1c5f6edf57e8915a738e5d057f388895c13cbbd8eaca0f423273</originalsourceid><addsrcrecordid>eNpd0E1LAzEQBuAgiq3VvyABL14WNsnm61hLrYWCIu15SZMJTWmz6ybrx793xXrxNDA878swZ2hMCS8LQip9jsaEM1YwwvUIXaW0L0smtGaXaESlkEIINkabtYlpF2ITAS-XUzz_hC4nbCKexjysbbDQ5vAOeO492IxDxK9mEB8h7_DMRAtdEaLrLTj88NPyYkK8RhfeHBLcnOYEbR7n69lTsXpeLGfTVdFSpnPhBFBirKmk9o5Y7gU4zyUoTbiRTAF3JZeeKaU0t4TZ7dYpGAKlryijkk3Q_W9v2zVvPaRcH0OycDiYCE2faqJoxSuuKBno3T-6b_ouDtfVVHBREs4pG9TtSfXbI7i67cLRdF_138PYN5KKZsg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2656015523</pqid></control><display><type>article</type><title>Tanshinone IIA Exerts an Antinociceptive Effect in Rats with Cancer-induced Bone Pain</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hao, Wei ; Chen, Lei ; Wu, Li-Fang ; Yang, Fan ; Niu, Jian-Xiang ; Kaye, Alan D ; Xu, Shi-Yuan</creator><creatorcontrib>Hao, Wei ; Chen, Lei ; Wu, Li-Fang ; Yang, Fan ; Niu, Jian-Xiang ; Kaye, Alan D ; Xu, Shi-Yuan</creatorcontrib><description>Cancer-induced bone pain (CIBP) is a common chronic pain characterized by 2 components, ongoing pain and breakthrough pain. Tanshinone IIA (TSN IIA) is a bioactive constituent of the traditional Chinese medicine Danshen, which has been reported to have an antinociceptive effect on neuropathic and inflammatory pain through downregulation of the late proinflammatory cytokine high-mobility group protein B1 (HMGB1).
To assess the antinociceptive effect of TSN IIA on CIBP.
A randomized, double-blind, controlled animal trial was performed.
University lab in China.
A rat CIBP model was established by injecting Walker 256 mammary gland carcinoma cells into the intramedullary cavity of the tibia. Both ongoing pain, e.g., flinching and guarding, and breakthrough pain, e.g., limb use and von Frey threshold, were evaluated. The effects of intraperitoneally administered TSN IIA on pain behavior and the expression levels of spinal HMGB1, interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6 were determined. The effect of TSN IIA on the electrically evoked response of spinal wide-dynamic range (WDR) neurons was performed in vivo.
TSN IIA dose-dependently inhibited cancer-induced ongoing pain and breakthrough pain. The expression levels of spinal HMGB1 and other inflammatory factors (IL-1beta, TNF-alpha, and IL-6) were increased in the rat model, but they were suppressed by TSN IIA in a dose-dependent manner. Moreover, TSN IIA significantly inhibited the neuronal responses of WDR neurons in spinal deep layers.
Further studies are warranted to ascertain how TSN IIA attenuates cancer-induced ongoing pain.
Our results indicate that TSN IIA attenuates cancer-induced ongoing pain and breakthrough pain, possibly via suppression of central sensitization in CIBP rats. Therefore, we have provided strong evidence supporting TSN IIA as a potential and effective therapy for relieving CIBP.
Cancer-induced bone pain, high-mobility group protein B1, Tanshinone IIA, ongoing pain, breakthrough pain.</description><identifier>ISSN: 1533-3159</identifier><identifier>EISSN: 2150-1149</identifier><identifier>PMID: 27676663</identifier><language>eng</language><publisher>United States: American Society of Interventional Pain Physician</publisher><subject>Analgesics ; Animals ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Bone Neoplasms - complications ; Cancer ; China ; Diterpenes, Abietane - therapeutic use ; Double-Blind Method ; Pain ; Pain - drug therapy ; Rats ; Rats, Sprague-Dawley ; Tumor necrosis factor-TNF</subject><ispartof>Pain physician, 2016-09, Vol.19 (7), p.465-476</ispartof><rights>2016. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27676663$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hao, Wei</creatorcontrib><creatorcontrib>Chen, Lei</creatorcontrib><creatorcontrib>Wu, Li-Fang</creatorcontrib><creatorcontrib>Yang, Fan</creatorcontrib><creatorcontrib>Niu, Jian-Xiang</creatorcontrib><creatorcontrib>Kaye, Alan D</creatorcontrib><creatorcontrib>Xu, Shi-Yuan</creatorcontrib><title>Tanshinone IIA Exerts an Antinociceptive Effect in Rats with Cancer-induced Bone Pain</title><title>Pain physician</title><addtitle>Pain Physician</addtitle><description>Cancer-induced bone pain (CIBP) is a common chronic pain characterized by 2 components, ongoing pain and breakthrough pain. Tanshinone IIA (TSN IIA) is a bioactive constituent of the traditional Chinese medicine Danshen, which has been reported to have an antinociceptive effect on neuropathic and inflammatory pain through downregulation of the late proinflammatory cytokine high-mobility group protein B1 (HMGB1).
To assess the antinociceptive effect of TSN IIA on CIBP.
A randomized, double-blind, controlled animal trial was performed.
University lab in China.
A rat CIBP model was established by injecting Walker 256 mammary gland carcinoma cells into the intramedullary cavity of the tibia. Both ongoing pain, e.g., flinching and guarding, and breakthrough pain, e.g., limb use and von Frey threshold, were evaluated. The effects of intraperitoneally administered TSN IIA on pain behavior and the expression levels of spinal HMGB1, interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6 were determined. The effect of TSN IIA on the electrically evoked response of spinal wide-dynamic range (WDR) neurons was performed in vivo.
TSN IIA dose-dependently inhibited cancer-induced ongoing pain and breakthrough pain. The expression levels of spinal HMGB1 and other inflammatory factors (IL-1beta, TNF-alpha, and IL-6) were increased in the rat model, but they were suppressed by TSN IIA in a dose-dependent manner. Moreover, TSN IIA significantly inhibited the neuronal responses of WDR neurons in spinal deep layers.
Further studies are warranted to ascertain how TSN IIA attenuates cancer-induced ongoing pain.
Our results indicate that TSN IIA attenuates cancer-induced ongoing pain and breakthrough pain, possibly via suppression of central sensitization in CIBP rats. Therefore, we have provided strong evidence supporting TSN IIA as a potential and effective therapy for relieving CIBP.
Cancer-induced bone pain, high-mobility group protein B1, Tanshinone IIA, ongoing pain, breakthrough pain.</description><subject>Analgesics</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Bone Neoplasms - complications</subject><subject>Cancer</subject><subject>China</subject><subject>Diterpenes, Abietane - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Pain</subject><subject>Pain - drug therapy</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Tumor necrosis factor-TNF</subject><issn>1533-3159</issn><issn>2150-1149</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpd0E1LAzEQBuAgiq3VvyABL14WNsnm61hLrYWCIu15SZMJTWmz6ybrx793xXrxNDA878swZ2hMCS8LQip9jsaEM1YwwvUIXaW0L0smtGaXaESlkEIINkabtYlpF2ITAS-XUzz_hC4nbCKexjysbbDQ5vAOeO492IxDxK9mEB8h7_DMRAtdEaLrLTj88NPyYkK8RhfeHBLcnOYEbR7n69lTsXpeLGfTVdFSpnPhBFBirKmk9o5Y7gU4zyUoTbiRTAF3JZeeKaU0t4TZ7dYpGAKlryijkk3Q_W9v2zVvPaRcH0OycDiYCE2faqJoxSuuKBno3T-6b_ouDtfVVHBREs4pG9TtSfXbI7i67cLRdF_138PYN5KKZsg</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Hao, Wei</creator><creator>Chen, Lei</creator><creator>Wu, Li-Fang</creator><creator>Yang, Fan</creator><creator>Niu, Jian-Xiang</creator><creator>Kaye, Alan D</creator><creator>Xu, Shi-Yuan</creator><general>American Society of Interventional Pain Physician</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160901</creationdate><title>Tanshinone IIA Exerts an Antinociceptive Effect in Rats with Cancer-induced Bone Pain</title><author>Hao, Wei ; Chen, Lei ; Wu, Li-Fang ; Yang, Fan ; Niu, Jian-Xiang ; Kaye, Alan D ; Xu, Shi-Yuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-d6e21aca479fd1c5f6edf57e8915a738e5d057f388895c13cbbd8eaca0f423273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analgesics</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Bone Neoplasms - complications</topic><topic>Cancer</topic><topic>China</topic><topic>Diterpenes, Abietane - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Pain</topic><topic>Pain - drug therapy</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hao, Wei</creatorcontrib><creatorcontrib>Chen, Lei</creatorcontrib><creatorcontrib>Wu, Li-Fang</creatorcontrib><creatorcontrib>Yang, Fan</creatorcontrib><creatorcontrib>Niu, Jian-Xiang</creatorcontrib><creatorcontrib>Kaye, Alan D</creatorcontrib><creatorcontrib>Xu, Shi-Yuan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pain physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hao, Wei</au><au>Chen, Lei</au><au>Wu, Li-Fang</au><au>Yang, Fan</au><au>Niu, Jian-Xiang</au><au>Kaye, Alan D</au><au>Xu, Shi-Yuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tanshinone IIA Exerts an Antinociceptive Effect in Rats with Cancer-induced Bone Pain</atitle><jtitle>Pain physician</jtitle><addtitle>Pain Physician</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>19</volume><issue>7</issue><spage>465</spage><epage>476</epage><pages>465-476</pages><issn>1533-3159</issn><eissn>2150-1149</eissn><abstract>Cancer-induced bone pain (CIBP) is a common chronic pain characterized by 2 components, ongoing pain and breakthrough pain. Tanshinone IIA (TSN IIA) is a bioactive constituent of the traditional Chinese medicine Danshen, which has been reported to have an antinociceptive effect on neuropathic and inflammatory pain through downregulation of the late proinflammatory cytokine high-mobility group protein B1 (HMGB1).
To assess the antinociceptive effect of TSN IIA on CIBP.
A randomized, double-blind, controlled animal trial was performed.
University lab in China.
A rat CIBP model was established by injecting Walker 256 mammary gland carcinoma cells into the intramedullary cavity of the tibia. Both ongoing pain, e.g., flinching and guarding, and breakthrough pain, e.g., limb use and von Frey threshold, were evaluated. The effects of intraperitoneally administered TSN IIA on pain behavior and the expression levels of spinal HMGB1, interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6 were determined. The effect of TSN IIA on the electrically evoked response of spinal wide-dynamic range (WDR) neurons was performed in vivo.
TSN IIA dose-dependently inhibited cancer-induced ongoing pain and breakthrough pain. The expression levels of spinal HMGB1 and other inflammatory factors (IL-1beta, TNF-alpha, and IL-6) were increased in the rat model, but they were suppressed by TSN IIA in a dose-dependent manner. Moreover, TSN IIA significantly inhibited the neuronal responses of WDR neurons in spinal deep layers.
Further studies are warranted to ascertain how TSN IIA attenuates cancer-induced ongoing pain.
Our results indicate that TSN IIA attenuates cancer-induced ongoing pain and breakthrough pain, possibly via suppression of central sensitization in CIBP rats. Therefore, we have provided strong evidence supporting TSN IIA as a potential and effective therapy for relieving CIBP.
Cancer-induced bone pain, high-mobility group protein B1, Tanshinone IIA, ongoing pain, breakthrough pain.</abstract><cop>United States</cop><pub>American Society of Interventional Pain Physician</pub><pmid>27676663</pmid><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1533-3159 |
| ispartof | Pain physician, 2016-09, Vol.19 (7), p.465-476 |
| issn | 1533-3159 2150-1149 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1824545821 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Analgesics Animals Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Bone Neoplasms - complications Cancer China Diterpenes, Abietane - therapeutic use Double-Blind Method Pain Pain - drug therapy Rats Rats, Sprague-Dawley Tumor necrosis factor-TNF |
| title | Tanshinone IIA Exerts an Antinociceptive Effect in Rats with Cancer-induced Bone Pain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A11%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tanshinone%20IIA%20Exerts%20an%20Antinociceptive%20Effect%20in%20Rats%20with%20Cancer-induced%20Bone%20Pain&rft.jtitle=Pain%20physician&rft.au=Hao,%20Wei&rft.date=2016-09-01&rft.volume=19&rft.issue=7&rft.spage=465&rft.epage=476&rft.pages=465-476&rft.issn=1533-3159&rft.eissn=2150-1149&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1824545821%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2656015523&rft_id=info:pmid/27676663&rfr_iscdi=true |